Fresenius Kabi Receives CMS Approval for COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
Fresenius Kabi, a subsidiary of Fresenius and a global leader in essential medicines and medical technologies, has announced a significant reimbursement milestone for its biologic therapy Tyenne® (tocilizumab-aazg). The Centers for Medicare & Medicaid Services (CMS) has issued new indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne when used in the treatment of COVID-19. These newly designated codes became effective for Medicare claims starting April 1, 2026, marking an important step forward in facilitating patient access and simplifying reimbursement processes for healthcare providers.
The assignment of these HCPCS codes is particularly important in the context of COVID-19 treatment, where timely access to therapies and streamlined administrative procedures remain critical. The new codes include Q0238 for injection, M0233 for the first dose of intravenous infusion, and M0234 for the second dose of intravenous infusion. Together, these codes enable healthcare providers to accurately bill and receive reimbursement for Tyenne when administered to eligible patients diagnosed with COVID-19, in accordance with its approved labeling by the U.S. Food and Drug Administration (FDA).
HCPCS codes play a central role in the U.S. healthcare reimbursement system. They are used by Medicare, Medicaid, and commercial insurers to standardize the reporting of medical procedures, services, and drugs. For medications like Tyenne that are administered via injection or infusion, these codes ensure that providers can submit claims efficiently and consistently, reducing administrative burden and minimizing delays in reimbursement. By introducing indication-specific codes for COVID-19, CMS is enhancing the clarity and precision of the billing process, which is especially important in complex treatment environments such as hospitals and infusion centers.
Molly Benson, Senior Vice President of Biopharma at Fresenius Kabi USA, emphasized the importance of this development in supporting both providers and patients. She noted that the establishment of indication-specific codes for COVID-19 represents a meaningful advancement in improving access to Tyenne. Clear and distinct coding, she explained, helps streamline claims processing and reinforces the company’s commitment to ensuring that patients who may benefit from this therapy can receive it without unnecessary administrative hurdles.
Tyenne, a biosimilar to tocilizumab, is part of a class of immunomodulatory therapies that target inflammatory pathways, making it relevant in the treatment of certain severe COVID-19 cases where immune overactivation can lead to complications. The availability of precise reimbursement codes ensures that providers can confidently incorporate the therapy into treatment protocols when clinically appropriate, knowing that billing pathways are well-defined and supported.
Prior to this announcement, Tyenne had already been assigned a permanent, product-specific Q-code for its approved autoimmune indications. These include conditions such as rheumatoid arthritis and other inflammatory disorders, where tocilizumab-based therapies have demonstrated clinical benefit. The addition of COVID-19-specific HCPCS codes expands the reimbursement framework for Tyenne, allowing it to be more seamlessly utilized across different therapeutic contexts and care settings.
This development also reflects broader efforts within the healthcare system to adapt coding and reimbursement mechanisms in response to evolving clinical needs. During the COVID-19 pandemic and its aftermath, regulatory agencies and payers have worked to ensure that effective treatments can be rapidly integrated into care delivery models. Indication-specific coding is one such mechanism that improves transparency and aligns reimbursement with clinical use, ultimately supporting better patient outcomes.
Beyond coding and reimbursement, Fresenius Kabi continues to invest in patient support and access initiatives. The company’s KabiCare™ patient services hub is designed to provide comprehensive assistance to patients and healthcare providers, including educational resources, financial support information, and guidance on navigating treatment options. Such programs are increasingly important in ensuring that innovative and essential therapies reach the patients who need them most.
In summary, the issuance of COVID-19-specific HCPCS codes for Tyenne by CMS represents a key milestone in enhancing access to this important therapy. By enabling accurate billing and efficient reimbursement, these codes support healthcare providers in delivering timely treatment while reducing administrative complexity. As the healthcare landscape continues to evolve, initiatives like this underscore the importance of aligning regulatory, clinical, and reimbursement frameworks to ensure optimal patient care.
About Tyenne®, a tocilizumab biosimilar
Tyenne® (tocilizumab-aazg), a biosimilar to Actemra® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced analytical and manufacturing technologies for use in the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving the product. Tyenne is contraindicated in patients with known hypersensitivity to tocilizumab products.
Source Link:https://www.businesswire.com/
